GenVivo
Biotechnology company developing in vivo gene-vector immunotherapies for oncology. The organization designs retroviral-based vector platforms (integrating and non-integrating) for systemic delivery of therapeutic genes, maintains in‑house process development and cGMP manufacturing, and conducts preclinical and early-phase clinical programs to advance candidate genetic medicines toward IND and clinical evaluation.
Industries
Nr. of Employees
small (1-50)
Products
In vivo CAR‑T/NK gene vector for B‑cell malignancies
Systemic vector designed to generate CAR‑expressing T cells and NK cells in patients to target B‑cell cancers.
Dual‑payload immunocytokine vector (IL‑12 + suicide gene) for solid tumors
Vector encoding an immune‑activating cytokine alongside a pro‑drug‑activated suicide gene intended to induce local immune activation and controllable tumor cell killing.
Immunocytokine vector (GM‑CSF + suicide gene) for solid tumors
Vector encoding a myeloid growth factor with a pro‑drug‑activated suicide gene to stimulate anti‑tumor immunity with an incorporated safety mechanism.
In vivo CAR‑T/NK gene vector for B‑cell malignancies
Systemic vector designed to generate CAR‑expressing T cells and NK cells in patients to target B‑cell cancers.
Dual‑payload immunocytokine vector (IL‑12 + suicide gene) for solid tumors
Vector encoding an immune‑activating cytokine alongside a pro‑drug‑activated suicide gene intended to induce local immune activation and controllable tumor cell killing.
Immunocytokine vector (GM‑CSF + suicide gene) for solid tumors
Vector encoding a myeloid growth factor with a pro‑drug‑activated suicide gene to stimulate anti‑tumor immunity with an incorporated safety mechanism.
Services
cGMP vector manufacturing and clinical supply
End-to-end in-house manufacturing services including master cell bank creation, drug substance and drug product production, and finished vial packaging for clinical trials.
Process development and technical transfer
Process design, optimization, QbD implementation, technical transfer and facility/equipment start-up to enable scalable vector production.
Preclinical safety and efficacy studies
Conduct of in‑house preclinical studies to evaluate safety, toxicology, and anti-tumor efficacy in animal models to support IND-enabling packages.
Clinical operations and study support
Protocol development, project management, monitoring, data management, biostatistics, pharmacovigilance, and trial supply management to execute early-phase clinical trials.
Analytical assay development and QC testing
Development and qualification of in‑house analytical and cell‑based assays for product release, stability, and investigation support.
cGMP vector manufacturing and clinical supply
End-to-end in-house manufacturing services including master cell bank creation, drug substance and drug product production, and finished vial packaging for clinical trials.
Process development and technical transfer
Process design, optimization, QbD implementation, technical transfer and facility/equipment start-up to enable scalable vector production.
Preclinical safety and efficacy studies
Conduct of in‑house preclinical studies to evaluate safety, toxicology, and anti-tumor efficacy in animal models to support IND-enabling packages.
Clinical operations and study support
Protocol development, project management, monitoring, data management, biostatistics, pharmacovigilance, and trial supply management to execute early-phase clinical trials.
Analytical assay development and QC testing
Development and qualification of in‑house analytical and cell‑based assays for product release, stability, and investigation support.
Expertise Areas
- Gene therapy vector development
- Viral vector biomanufacturing (cGMP)
- Process development and scale-up
- Preclinical safety and efficacy evaluation
Key Technologies
- Retroviral vector platforms (integrating and non‑integrating)
- In vivo CAR vector generation
- Immunocytokine gene delivery
- Suicide gene/pro‑drug systems